Shell Asset Management Company held Roivant Sciences Ltd. during the second quarter. (NASDAQ: ROIV – Get Rating) , according to the company’s most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,571 shares of the company’s stock, valued at approximately $120,000.
Other large investors have also made changes to their positions in the company recently. American International Group Inc. bought a new position in Roivent Sciences during the first quarter worth $8,965,000. Eventide Asset Management LLC increased its position in Roevent Sciences by 141.5% during the first quarter. Eventide Asset Management LLC now owns 1,690,300 shares of the company’s stock valued at $8,177,000 after acquiring an additional 990,300 shares during the period. Chicago Capital LLC acquired a new stake in Roiven Sciences in the second quarter valued at approximately $3,818,000. Two Seas Capital LP raised its holding in Roivant Sciences to 159.4% in the first quarter. Two Seas Capital LP now owns 806,907 shares of the company’s stock valued at $3,986,000 after purchasing an additional 495,862 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Roivent Sciences to 13.8% during the first quarter. After buying an additional 159,787 shares last quarter, Vanguard Group Inc. holds 1,319,499 shares of the company’s stock valued at $6,519,000. Institutional investors hold 51.44% of the company’s stock.
Wall Street analysts weigh in
Several research firms have weighed in on ROIV recently. Citigroup raised its price target on shares of Roivant Sciences from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday. SVB Leerink raised its target price on Roivant Sciences from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. initiated coverage on Roivant Sciences in a research report on Thursday, October 27. He issued an “overweight” rating and $7.00 price target on the stock. According to MarketBeat.com, six research analysts have Buy ratings on the stock, with a current average rating of “Buy” and an average target price of $11.17.
Insider trading at Roivant Sciences
In other Roivant Sciences news, major shareholder Pharma Technologies Ltd Dexcel acquired 4,000,000 shares of Roivant Sciences stock in a transaction that took place on Thursday, November 10. The shares were acquired at an average cost of $5.00 per share for an aggregate value of $20,000,000.00. Following completion of the purchase, the Insider now directly owns 102,849,443 shares of Company stock, valued at approximately $514,247,215. The acquisition was disclosed in a legal filing with the Securities and Exchange Commission, which is available through the SEC website. In related news, major shareholder Pharma Technologies Ltd Dexcel acquired 4,000,000 shares of the stock in a transaction that took place on Thursday, November 10. The stock was acquired at an average cost of $5.00 per share for a transaction totaling $20,000,000.00. Following the transaction, the insider now directly owns 102,849,443 shares in the company, valued at $514,247,215. The transaction was disclosed in a filing with the Securities and Exchange Commission, which is available via this hyperlink. Besides, Directors Financial Lp Qvt sold 5,656,081 shares of the stock in a transaction that happened on Thursday, Nov 10. Shares were sold at an average price of $4.75, for a total transaction of $26,866,384.75. Following completion of the transaction, the Director now directly owns 5,470,181 shares of Company stock, valued at approximately $25,983,359.75. Disclosure of this sale can be found here. In the last quarter, insiders sold 5,771,244 shares of company stock valued at $27,293,303. Corporate insiders own 13.00% of the company’s stock.
Roivant Sciences stock down 5.1%
The NASDAQ ROIV opened at $5.00 on Friday. The fifty day moving average price of the trade is $4.34 and the two hundred day moving average price is $4.12. The stock has a market capitalization of $3.52 billion, a PE ratio of -2.94, and a beta of 1.89. Roivant Sciences Ltd. has a 52 week low of $2.52 and a 52 week high of $16.76. The company has a debt-to-equity ratio of 0.25, a current ratio of 7.43, and a quick ratio of 6.20.
Roivant Science Profile
Roivant Sciences Ltd., is a biopharmaceutical and healthcare technology company engaged in research and development of medicines. The company develops product candidates for the treatment of various therapeutics including solid tumors, sickle cell disease, hypophosphatasia, oncological malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye disease, sarcoidosis. and staph aureus bacteremia.
Want to see what other hedge funds are holding ROIVs? Roivant Sciences Ltd. (NASDAQ: ROIV – Get Rating) Visit HoldingsChannel.com to get the latest 13F filings and insider trades.
Receive news and ratings for Roivant Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Roivant Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.